As of September 18, 2026, the stock is trading at ₹928.5, with a generally bullish technical stance across multiple timeframes. Daily, weekly, and monthly indicators suggest an uptrend, with the price trading above key moving averages like the 20-day, 50-day, and 200-day Simple Moving Averages (SMAs), as well as the 20-day and 50-day Exponential Moving Averages (EMAs) and the Supertrend indicator on the daily chart. This alignment across timeframes indicates a strong underlying positive trend. The stock is positioned approximately 88% of the way up its 252-day trading range, suggesting it is trading near its recent highs. However, a "Bearish Engulfing Reversal" pattern was observed on the weekly timeframe on September 18, 2026, which could signal a potential short-term pause or reversal. The stock's annualized volatility stands at 31%, with a current drawdown of -3%.

Nearest support is observed around ₹923.32 (0.56% below the current price), followed by ₹920.0 (0.92% below). Overhead resistance is noted at ₹936.63 (0.88% above the current price), with further levels at ₹942.6 (1.52% above) and ₹945.87 (1.87% above). The recent anomaly on September 18, 2026, showed "high participation no clear direction" on the daily timeframe with an extreme Z-score of 11.89 and a volume ratio of 6.31, indicating significant trading activity without a decisive price move, which warrants close observation.

Anthem Biosciences Limited announced on September 8, 2026, the settlement of an upside sharing arrangement valued at approximately ₹1,276.83 million. This settlement, which involved Upside Principal Shareholders Mr. Ajay Bhardwaj, Mr. Ganesh Sambasivam, and Mr. K. Ravindra Chandrappa, followed shareholder approval at the Annual General Meeting on July 22, 2026, and a prior agreement dated December 30, 2024. This development relates to a divestment by Viridity Tone LLP.

Earlier in the week, on July 27, 2026, the company reported its Q1 FY27 results. Consolidated revenues reached ₹418 crores, with the CRDMO segment contributing ₹341 crores and Specialty Ingredients ₹78 crores. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at ₹176 crores, representing a 39.6% margin, and Profit After Tax was ₹120 crores, a 27.1% margin. The company indicated that while underlying demand remains strong, timing shifts in customer deliveries mean a higher concentration of deliveries are expected in the second half of the fiscal year. As of June 30, 2026, the company's net cash position was ₹1,720 crores. The company also held its 20th Annual General Meeting on July 22, 2026, where all presented resolutions, including financial statement adoption and dividend declaration, were passed.

As of September 18, 2026, Anthem Biosciences (ANTHEM) on the NSE has experienced a slight increase in its stock price, moving from ₹927.4 to ₹928.5. This change occurred between the observation date of the previous price and the current report date. No new filings or news developments have been reported recently that would provide additional context for this price movement. The company's profile and listing on the NSE remain unchanged.

Anthem Biosciences Limited has finalized an upside sharing arrangement, settling approximately ₹1,276.83 million with specific principal shareholders. This settlement follows shareholder approval at the Annual General Meeting on July 22, 2026, and a prior agreement from December 30, 2024, related to a divestment by Viridity Tone LLP. The company also reported its financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), ending June 30, 2026. Consolidated revenues reached ₹4,182 million, with the CRDMO segment contributing ₹3,408 million and Specialty Ingredients ₹774 million. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) were ₹1,755 million, representing a 39.6% margin, and Profit After Tax (PAT) was ₹1,199 million, with a 27.1% margin. The company noted that timing shifts in customer deliveries affected the quarter, but underlying demand remains strong, with a greater concentration of deliveries anticipated in the second half of the fiscal year. As of June 30, 2026, the company maintained a net cash position of ₹17,197 million. The Board of Directors also approved the allotment of 1,670,909 equity shares under its ESOP Scheme 2024.

Anthem Biosciences reported a mixed operating trajectory across recent periods. For the quarter ending June 2026 (Q1 FY27), the company posted Revenue from Operations of ₹418.22 crore, a decrease from ₹610.94 crore in the prior quarter (Q4 FY26). However, Net Profit for Q1 FY27 was ₹119.94 crore, an increase from ₹189.76 crore in Q4 FY26, indicating a potential shift in profitability drivers. The operating profit margin (OPM) for Q1 FY27 stood at 36.0%, compared to 44.0% in Q4 FY26, suggesting some pressure on operational efficiency.

Looking at the balance sheet, the company has managed its debt levels effectively. Borrowings decreased from ₹239 crore in March 2024 to ₹113 crore in March 2025, and are projected to further decrease to ₹54 crore by March 2026. This reduction in debt, coupled with a growing Equity Capital and Reserves, has led to a very low Debt Equity Ratio, reported at 0.0118 in Q1 FY27. The company's cash flow from operations has shown variability, with ₹140.0 crore in March 2024, a projected ₹271.0 crore in March 2025, and a significant increase to ₹844.0 crore by March 2026. Free Cash Flow turned negative in March 2024 at -₹156.0 crore, but is projected to recover to ₹12.0 crore in March 2025 and ₹637.0 crore in March 2026.

Key areas to monitor include the sustainability of the projected increase in operating cash flow, the management of inventory days which have fluctuated significantly, and the impact of increased fixed assets and investments on future returns.

Anthem Biosciences shows several constructive financial and technical indicators. The company's cash flow from operations has significantly increased, projected to rise from ₹271.0 crore in March 2025 to ₹844.0 crore in March 2026. This growth is reflected in a substantial improvement in free cash flow, expected to jump from ₹12.0 crore to ₹637.0 crore over the same period. Furthermore, the company has demonstrated consistent profit growth, with a compounded profit growth of 17% over 5 years and 18% on a trailing twelve months (TTM) basis. Technically, multiple timeframes (daily, weekly, and monthly) indicate a bullish trend, supported by indicators such as the Supertrend direction and positive Exponential Moving Average (EMA) slopes.

Anthem Biosciences faces potential headwinds related to its sales performance and investment activities. While profit growth has been robust over the last five years and on a trailing twelve-month (TTM) basis, sales growth has contracted by 2% in the TTM period, contrasting with a 14% compounded growth over five years. This divergence warrants monitoring. Furthermore, the company's cash flow from investing activities has significantly increased from ₹147 crore in March 2025 to ₹702 crore in March 2026, alongside a substantial rise in investments from ₹433 crore to ₹1007 crore over the same periods. This escalation in investment spending, coupled with a notable increase in Cash from Operating Activity from ₹271 crore to ₹844 crore, has resulted in a substantial increase in Free Cash Flow from ₹12 crore to ₹637 crore, but the increased investing outflow has also led to a higher Net Cash Flow of ₹103 crore in March 2026 compared to a negative ₹12 crore in March 2025.